ArticleFrontiers in pharmacology2022

Wnt-pathway inhibitors with selective activity against triple-negative breast cancer: From thienopyrimidine to quinazoline inhibitors.

Cédric Boudou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.